{"DataElement":{"publicId":"3652830","version":"1","preferredName":"Hormone Therapy Tamoxifen Received Age Number","preferredDefinition":"Information related to patient/participant having received Tamoxifen which is an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1)._Age","longName":"2405038v1.0:2760628v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2405038","version":"1","preferredName":"Hormone Therapy Tamoxifen Received","preferredDefinition":"Information related to patient/participant having received Tamoxifen which is an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1).","longName":"HORMTX_TAM_RCVD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2433915","version":"1","preferredName":"Hormone Therapy","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA8-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2743363","version":"1","preferredName":"Tamoxifen Received","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04):Received; taken, gotten, or acquired.","longName":"C855:C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B282084-20BF-6A3A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-18","modifiedBy":"ONEDATA","dateModified":"2008-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0EBA-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-09-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2760628","version":"1","preferredName":"Age Number","preferredDefinition":"Age","longName":"2760628v1.0","context":"PS-CC","contextVersion":"1","type":"Non-enumerated","dataType":"java.lang.Integer","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008581","version":"1","preferredName":"Properties or Attributes","preferredDefinition":"NCI Thesarurus C20189","longName":"PropertiesOrAttributes","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C4F36F0A-BEBB-047F-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-08-15","endDate":null,"createdBy":"DWARZEL","dateCreated":"2003-08-15","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233101","version":"1","preferredName":"Number","preferredDefinition":"Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.","longName":"C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F920A342-1134-2A6A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"501F2599-2A30-4A4E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-20","endDate":null,"createdBy":"UMLLOADER_HINTS","dateCreated":"2008-06-20","modifiedBy":"COOPERM","dateModified":"2011-10-26","changeDescription":"Released VD for use by UAMS CDE. mc 10/26/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"How old were you when you fir","type":"Preferred Question Text","description":"How old were you when you first started using tamoxifen?","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D36B1B10-B16D-45C4-E040-BB89AD4326AB","latestVersionIndicator":"Yes","beginDate":"2013-01-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2013-01-16","modifiedBy":"RODGERSC","dateModified":"2015-02-25","changeDescription":"created for UAMS cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}